Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma.
Fiche publication
Date publication
avril 2017
Journal
The New England journal of medicine
Auteurs
Membres identifiés du Cancéropôle Est :
Dr CAILLOT Denis
Tous les auteurs :
Attal M, Lauwers-Cances V, Hulin C, Leleu X, Caillot D, Escoffre M, Arnulf B, Macro M, Belhadj K, Garderet L, Roussel M, Payen C, Mathiot C, Fermand JP, Meuleman N, Rollet S, Maglio ME, Zeytoonjian AA, Weller EA, Munshi N, Anderson KC, Richardson PG, Facon T, Avet-Loiseau H, Harousseau JL, Moreau P,
Lien Pubmed
Résumé
High-dose chemotherapy plus autologous stem-cell transplantation has been the standard treatment for newly diagnosed multiple myeloma in adults up to 65 years of age. However, promising data on the use of combination therapy with lenalidomide, bortezomib, and dexamethasone (RVD) in this population have raised questions about the role and timing of transplantation.
Mots clés
Adult, Aged, Antineoplastic Combined Chemotherapy Protocols, adverse effects, Bortezomib, administration & dosage, Combined Modality Therapy, Dexamethasone, administration & dosage, Disease-Free Survival, Female, Humans, Induction Chemotherapy, Kaplan-Meier Estimate, Maintenance Chemotherapy, Male, Middle Aged, Multiple Myeloma, drug therapy, Salvage Therapy, Stem Cell Transplantation, Thalidomide, administration & dosage, Transplantation, Autologous
Référence
N. Engl. J. Med.. 2017 04;376(14):1311-1320